Precision Medicine

Elephas Biosciences adds legendary oncologist Dr. Skip Burris to its board, a pivotal move to commercialize a platform that predicts immunotherapy success.

CEO CarolAnn Tutera's recent accolade signals a mainstream shift. We decode the market strategy and regulatory landscape of her hormone therapy enterprise.

Viz.ai expands its AI care platform into neurodegenerative disease, partnering with Cortechs.ai to bring quantitative neuroimaging to nearly 2,000 hospitals.

With a landmark NEJM publication and FDA approval, Rhythm Pharma's setmelanotide offers hope for a rare obesity, proving a potent strategy for niche markets.

Millions suffer through frequent eye injections for wet AMD. A new partnership aims to change that with a targeted drug and microneedle system, promising a precision strike at the disease's core.

CorePlus's landmark integration of an AI-powered test marks a pivotal moment for personalized medicine and health equity in the Caribbean.

A new study validates a blood test with near-perfect accuracy in MS relapse detection, signaling a strategic shift from imaging to biological data in neurology.

GeneCentric's ExpressCT Rewind™ uses fragmentomics to mine gene expression data from old liquid biopsies, offering a cost-effective way to find new biomarkers.

A new partnership aims to turn saliva into a data-rich asset, signaling a major shift in the health tech market from reactive treatment to proactive care.

A new startup is betting that sleep data is useless without a clinical path. Dumbo Health's SleepLongevityAge™ aims to turn tracker scores into treatment.

China's top probiotics firm, WONDERLAB, is challenging the 'calories in, calories out' model with a new framework for precision, microbiome-based weight loss.

With the appointment of Vita S. Salsman, Immunocine signals a major push to translate its unique "Double Loaded" dendritic cell therapy from lab to clinic.

A new company aims to fix a multi-billion dollar problem in drug development by using advanced biomarker tests to find the right patients before they even start.

AstraZeneca's new deal with genomics firm Helix isn't just a partnership; it's a bet on a future where drug discovery is driven by massive data vaults.

With €33M in fresh capital, Cyllene Therapeutics is advancing a novel gene therapy for bladder disease. We analyze the tech, the investors, and the plan.

For millions with the debilitating condition dysautonomia, diagnosis is a long, frustrating journey. A new technology promises to replace subjective guesswork with hard data.

Saol Therapeutics' NDA resubmission isn't just a second chance; it's a calculated maneuver signaling a new playbook for navigating the FDA in rare disease.

With €33M in new funding, Cyllene Therapeutics is advancing a novel gene therapy using HSV-1 vectors. Could this be the one-shot cure for millions?

CurifyLabs just raised $14M to put 3D printers in pharmacies. It’s more than a tech play; it’s a calculated bet on a new era of personalized medicine.

Vivos Inc. wins FDA approval for a human trial of RadioGel®, a targeted therapy that could offer new hope for patients with non-resectable thyroid cancer.